Felix Mahfoud

Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

Barbato E, Azizi M, Schmieder RE, Lauder L, Böhm M, Brouwers S, Bruno RM, Dudek D, Kahan T, Kandzari D, Lüscher T, Parati G, Pathak A, Ribichini F, Schlaich M, Sharp A, Sudano I, Volpe M, Tsioufis C, Wijns W, Mahfoud F

March 20, 2023 | 10.4244/EIJ-D-22-00723

Translational value of preclinical models for renal denervation: a histological comparison of human versus porcine renal nerve anatomy

Sato Y, Sharp A, Mahfoud F, Tunev S, Forster A, Ellis M, Gomez A, Dhingra R, Ullman J, Schlaich M, Lee D, Trudel J, Hettrick D, Kandzari D, Virmani R, Finn A

February 6, 2023 | 10.4244/EIJ-D-22-00369

Changes in blood pressure after crossover to ultrasound renal denervation in patients initially treated with sham in the RADIANCE-HTN SOLO trial

Mahfoud F, Bloch M, Azizi M, Wang Y, Schmieder RE, Lobo M, Sharp A, Daemen J, Basile J, Weber M, Scicli A, McClure C, Kirtane AJ

December 17, 2021 | 10.4244/EIJ-D-21-00295

Prioritised endpoints for device-based hypertension trials: the win ratio methodology

Kandzari D, Hickey G, Pocock S, Weber M, Böhm M, Cohen S, Fahy M, Lamberti G, Mahfoud F

April 2, 2021 | 10.4244/EIJ-D-20-01090

Immediate and long-term impact of the COVID-19 pandemic on cardiovascular clinical trials: considerations for study conduct and endpoint determination

Lansky A, Shah T, Wijns W, Stefanini G, Farb A, Kaplan A, Xu B, Pietras C, Velazquez E, Serruys P, Mahfoud F, Baumbach A

November 20, 2020 | 10.4244/EIJV16I10A147

Radiofrequency renal denervation is effective – and safe?

Mahfoud F, Kulenthiran S

May 20, 2020 | 10.4244/EIJV16I1A4

Bare metal or drug-eluting stent versus drug-coated balloon in non-ST-elevation myocardial infarction: the randomised PEPCAD NSTEMI trial

Scheller B, Ohlow M, Ewen S, Kische S, Rudolph T, Clever Y, Wagner A, Richter S, El-Garhy M, Böhm M, Degenhardt R, Mahfoud F, Lauer B

April 17, 2020 | 10.4244/EIJ-D-19-00723

The AFR-PRELIEVE trial: a prospective, non-randomised, pilot study to assess the Atrial Flow Regulator (AFR) in heart failure patients with either preserved or reduced ejection fraction

Paitazoglou C, Özdemir R, Pfister R, Bergmann M, Bartunek J, Kilic T, Lauten A, Schmeisser A, Zoghi M, Anker S, Sievert H, Mahfoud F

August 29, 2019 | 10.4244/EIJ-D-19-00342

Safety and performance of diagnostic electrical mapping of renal nerves in hypertensive patients

Tsioufis C, Feyz L, Dimitriadis K, Konstantinidis D, Tousoulis D, Voskuil M, Mahfoud F, Daemen J

December 20, 2018 | 10.4244/EIJ-D-18-00536

Will ORBITA change my practice? ORBITA trial: Objective Randomised Blinded Investigation with optimal medical Therapy of Angioplasty in stable angina

Schueler R, Al-Lamee R, Mahfoud F, Capodanno D, Asnag M, Haude M

October 19, 2018 | 10.4244/EIJY18M09_2

Evaluating the importance of sham-controlled trials in the investigation of medical devices in interventional cardiology

Byrne R, Capodanno D, Mahfoud F, Fajadet J, Windecker S, Jüni P, Baumbach A, Wijns W, Haude M

August 24, 2018 | 10.4244/EIJ-D-18-00481

Will SPYRAL HTN-ON MED change my practice? SPYRAL HTN-ON MED: a prospective, randomised, sham-controlled trial on renal denervation in the presence of antihypertensive medications

Ewen S, Lauder L, Azizi M, Kandzari D, Pathak A, Sharif F, Wijns W, Mahfoud F, Lüscher T

August 3, 2018 | 10.4244/EIJY18M07_1

Will SPYRAL HTN-OFF MED change my practice? SPYRAL HTN-OFF MED: a prospective, randomised, sham-controlled trial on renal denervation in the absence of antihypertensive medications

Lauder L, Ewen S, Azizi M, Mauri L, Lurz P, Lobo M, Sharif F, Wijns W, Tsioufis C, Mahfoud F

August 3, 2018 | 10.4244/EIJY18M07_2

Renal artery anatomy assessed by quantitative analysis of selective renal angiography in 1,000 patients with hypertension

Lauder L, Ewen S, Tzafriri A, Edelman E, Lüscher T, Blankestijn P, Dörr O, Schlaich M, Sharif F, Voskuil M, Zeller T, Ukena C, Scheller B, Böhm M, Mahfoud F

May 20, 2018 | 10.4244/EIJ-D-18-00112

Renal denervation for treatment of hypertension – will 2017 be the year of enlightenment?

Mahfoud F, Edelman E

April 7, 2017 | 10.4244/EIJV12I18A355

Will SPRINT change my practice? SPRINT: a randomised trial of intensive versus standard blood-pressure control

Ewen S, Lobo M, Pathak A, Schmieder RE, Tsioufis C, Wijns W, Mahfoud F

August 20, 2016 | 10.4244/EIJV12I6A132

Renal sympathetic nerve denervation using intraluminal ultrasound within a cooling balloon preserves the arterial wall and reduces sympathetic nerve activity

Pathak A, Coleman L, Roth A, Stanley J, Bailey L, Markham P, Ewen S, Morel C, Despas F, Honton B, Senard J, Fajadet J, Mahfoud F

August 20, 2015 | 10.4244/EIJV11I4A96

Renal denervation reloaded: where to go from here?

Mahfoud F, Serruys P

February 20, 2015 | 10.4244/EIJV10I10A187

From SYMPLICITY HTN-3 to the Renal Denervation Global Registry: where do we stand and where should we go?

Pathak A, Ewen S, Fajadet J, Honton B, Mahfoud F, Marco J, Schlaich M, Schmieder RE, Tsioufis C, Ukena C, Zeller T

May 20, 2014 | 10.4244/EIJV10I1A4

What the interventionalist should know about renal denervation in hypertensive patients: a position paper by the ESH WG on the interventional treatment of hypertension

Tsioufis C, Mahfoud F, Mancia G, Redon J, Damascelli B, Zeller T, Schmieder RE

January 20, 2014 | 10.4244/EIJV9I9A175

Felix Mahfoud

Latest news